INN monograph
Cholera Vaccine (parenteral)
Vaccine / immunological product · POM
Verified · Updated 01 Aug 2026 · Source: Local active-ingredient clinical extract; Professional class pharmacology (Vaccine / immunological product)
Kenya market
Wholesale / list prices where loaded
Risk first
Contraindications
- Anaphylaxis to prior dose or component.
- Live vaccines contraindicated in significant immunosuppression and usually pregnancy.
- Defer for moderate–severe acute illness.
Precautions
- Observe 15 minutes post-dose if high anaphylaxis concern.
- Correct injection technique and site.
- Report AEFI via national systems.
Point of care
Dosing
Adult
Adult and children over 10 yrs: S.C or I.M, 2 doses of 0.5ml administered at intervals of 1-4 wks. Booster dose: 0.5 ml 6 monthly. Children 5-10 yrs: S.C or I.M, 2 doses of 0.3 ml administered at intervals of 1-4 wks. Booster dose: 0.3 ml 6 monthly. Children 6 months to 5 yrs: S.C or I.M, 2 doses of 0.2ml administered at intervals of 1-4 wks. Booster dose: 0.2ml 6 monthly.Below 6 months.
Paediatric
See label paediatric section if present; otherwise use paediatric formulary — do not extrapolate adult doses.
Renal
N/A generally.
- CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
Hepatic
N/A generally.
Safety
Drug interactions
- Follow Kenya KEPI / MoH schedules.
- Never freeze freeze-sensitive vaccines incorrectly.
- Document batch and site.
- Separate true contraindications from precautions.
Safety
Adverse effects
- Local pain, low-grade fever, myalgia.
- Serious: anaphylaxis, vaccine-specific rare events (e.g. intussusception historically with some rotavirus products).
Use
Indications
- Prophylaxis against cholera caused by V. cholerae 01.
- Clinical selection for Cholera Vaccine (parenteral) should follow culture results where relevant, Kenya STG/EML recommendations, and the current product SmPC.
- Class context: Vaccine / immunological product.
- Confirm site-specific dose, duration and monitoring before prescribing.
Pharmacology
Mode of action
Vaccines present antigen to the adaptive immune system to generate protective antibodies and memory cells without causing full disease (or using attenuated/inactivated/subunit/mRNA platforms).
Full mechanism text
Vaccines present antigen to the adaptive immune system to generate protective antibodies and memory cells without causing full disease (or using attenuated/inactivated/subunit/mRNA platforms). Immunoglobulins provide passive temporary immunity.
ADME
Pharmacokinetics & PD
| Onset | Immune response days–weeks |
|---|---|
| Duration | Months–lifelong (schedule-dependent) |
| Route | IM / SC / ORAL / ID |
Kenya
Brands & prices
| Brand | Company | Pack | KES |
|---|---|---|---|
| Vibrio Cholerae Inaba | Independent / Registered Supplier | Standard Commercial Pack | — |
| Vibrio Cholerae Ogawa | Independent / Registered Supplier | Standard Commercial Pack | — |
| Vibrio Cholerae Polyvalent | Independent / Registered Supplier | Standard Commercial Pack | — |
Special populations
Pregnancy & lactation
Pregnancy
Inactivated vaccines (e.g. influenza, Tdap) often recommended; live vaccines generally avoided.
Lactation
Most vaccines compatible; live vaccines usually fine for breastfeeding mother.
Diet
Food & alcohol
- Food
Trust
Sources & disclaimer
Source: Local active-ingredient clinical extract; Professional class pharmacology (Vaccine / immunological product)
Last reviewed: 01 Aug 2026
Decision support only — not a substitute for clinical judgment, product SmPC, or Kenya STG/EML.